Dissociated resistance among fluoroquinolones
- PMID: 7811025
- PMCID: PMC284690
- DOI: 10.1128/AAC.38.9.2095
Dissociated resistance among fluoroquinolones
Abstract
A panel of 190 clinical isolates of staphylococci, enterococci, Streptococcus pneumoniae, members of the family Enterobacteriaceae, and nonfermentative gram-negative bacilli were examined by agar dilution tests for susceptibility to five quinolones and six nonquinolone agents. Members of the family Enterobacteriaceae and staphylococci were divided into subgroups according to their ciprofloxacin susceptibilities and were analyzed for cross-resistance to OPC-17116, ofloxacin, and temafloxacin. Although the MICs of all quinolones increased with increasing ciprofloxacin resistance, the MICs of OPC-17116, ofloxacin, and temafloxacin tended to increase less than those of ciprofloxacin, indicating that these agents were less affected by the mechanisms of quinolone resistance. An exception to this was the activity of OPC-17116 against highly ciprofloxacin-resistant staphylococci (MIC, > or = 8 micrograms/ml). Some of these staphylococci were equally resistant to OPC-17116, while others were fourfold more susceptible to ciprofloxacin than to OPC-17116. This indicated that in some strains OPC-17116 was more affected than ciprofloxacin by certain mechanisms responsible for high-level resistance. This was paralleled in single-step mutational studies in which 7 of 19 staphylococcal mutants exhibited large decreases in susceptibility to OPC-17116 (128- to 256-fold) but only modest decreases in susceptibility (4- to 16-fold) to the other quinolones. Such mutants were selected only from strains moderately resistant to ciprofloxacin (MIC, > or = 1 microgram/ml). This heterogeneity in the resistance of staphylococci to fluoroquinolones has not been seen previously and suggests that certain mechanisms of resistance in staphylococci affect OPC-17116 to a much greater extent than other quinolones.
Similar articles
-
In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):372-81. doi: 10.1007/BF01962081. Eur J Clin Microbiol Infect Dis. 1992. PMID: 1327789
-
The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.J Antimicrob Chemother. 1998 Aug;42(2):179-87. doi: 10.1093/jac/42.2.179. J Antimicrob Chemother. 1998. PMID: 9738835
-
In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.Antimicrob Agents Chemother. 1991 Nov;35(11):2329-34. doi: 10.1128/AAC.35.11.2329. Antimicrob Agents Chemother. 1991. PMID: 1804005 Free PMC article.
-
Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.Antimicrob Agents Chemother. 2000 Oct;44(10):2595-9. doi: 10.1128/AAC.44.10.2595-2599.2000. Antimicrob Agents Chemother. 2000. PMID: 10991829 Free PMC article. Review. No abstract available.
-
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria.Antimicrob Agents Chemother. 2000 Sep;44(9):2233-41. doi: 10.1128/AAC.44.9.2233-2241.2000. Antimicrob Agents Chemother. 2000. PMID: 10952561 Free PMC article. Review. No abstract available.
Cited by
-
Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.Eur J Clin Microbiol Infect Dis. 2005 Jun;24(6):405-10. doi: 10.1007/s10096-005-1344-4. Eur J Clin Microbiol Infect Dis. 2005. PMID: 15931454
-
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.Antimicrob Agents Chemother. 1996 Dec;40(12):2760-4. doi: 10.1128/AAC.40.12.2760. Antimicrob Agents Chemother. 1996. PMID: 9124836 Free PMC article.
-
Grepafloxacin.Drugs. 1997 May;53(5):817-24; discussion 825-7. doi: 10.2165/00003495-199753050-00007. Drugs. 1997. PMID: 9129868 Review.
-
In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci.Antimicrob Agents Chemother. 1998 Oct;42(10):2752-5. doi: 10.1128/AAC.42.10.2752. Antimicrob Agents Chemother. 1998. PMID: 9756791 Free PMC article.
-
The evolution of resistance to synergistic multi-drug combinations is more complex than evolving resistance to each individual drug component.Evol Appl. 2023 Nov 15;16(12):1901-1920. doi: 10.1111/eva.13608. eCollection 2023 Dec. Evol Appl. 2023. PMID: 38143903 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical